DE69621799D1 - Verwendung von gabapentin und seine derivate in der behandlung von manie und bipolare störungen - Google Patents

Verwendung von gabapentin und seine derivate in der behandlung von manie und bipolare störungen

Info

Publication number
DE69621799D1
DE69621799D1 DE69621799T DE69621799T DE69621799D1 DE 69621799 D1 DE69621799 D1 DE 69621799D1 DE 69621799 T DE69621799 T DE 69621799T DE 69621799 T DE69621799 T DE 69621799T DE 69621799 D1 DE69621799 D1 DE 69621799D1
Authority
DE
Germany
Prior art keywords
treatment
mania
gabapentin
derivatives
bipolar disorders
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
DE69621799T
Other languages
English (en)
Other versions
DE69621799T2 (de
Inventor
Chandra Pande
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Warner Lambert Co LLC
Original Assignee
Warner Lambert Co LLC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Warner Lambert Co LLC filed Critical Warner Lambert Co LLC
Publication of DE69621799D1 publication Critical patent/DE69621799D1/de
Application granted granted Critical
Publication of DE69621799T2 publication Critical patent/DE69621799T2/de
Anticipated expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Emergency Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Psychiatry (AREA)
  • Organic Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Beans For Foods Or Fodder (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Saccharide Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
DE69621799T 1995-05-15 1996-04-26 Verwendung von gabapentin und seine derivate in der behandlung von manie und bipolare störungen Expired - Fee Related DE69621799T2 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US08/440,570 US5510381A (en) 1995-05-15 1995-05-15 Method of treatment of mania and bipolar disorder
PCT/US1996/005898 WO1996036328A1 (en) 1995-05-15 1996-04-26 A method of treatment of mania and bipolar disorder

Publications (2)

Publication Number Publication Date
DE69621799D1 true DE69621799D1 (de) 2002-07-18
DE69621799T2 DE69621799T2 (de) 2003-01-02

Family

ID=23749281

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69621799T Expired - Fee Related DE69621799T2 (de) 1995-05-15 1996-04-26 Verwendung von gabapentin und seine derivate in der behandlung von manie und bipolare störungen

Country Status (19)

Country Link
US (1) US5510381A (de)
EP (1) EP0825857B1 (de)
JP (1) JPH11505244A (de)
AT (1) ATE218857T1 (de)
AU (1) AU702435B2 (de)
CA (1) CA2215923C (de)
CZ (1) CZ288072B6 (de)
DE (1) DE69621799T2 (de)
DK (1) DK0825857T3 (de)
EE (1) EE03420B1 (de)
ES (1) ES2177783T3 (de)
GE (1) GEP20002014B (de)
HU (1) HUP9802087A3 (de)
NO (1) NO315967B1 (de)
NZ (1) NZ307366A (de)
PT (1) PT825857E (de)
SK (1) SK281982B6 (de)
WO (1) WO1996036328A1 (de)
ZA (1) ZA963826B (de)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6372792B1 (en) 1996-04-26 2002-04-16 Guy Chouinard Method for treating anxiety, anxiety disorders and insomnia
PL189872B1 (pl) 1996-07-24 2005-10-31 Warner Lambert Co Zastosowanie izobutylogaby i jej pochodnych do wytwarzania leku do leczenia bólu
WO1999018063A2 (en) 1997-10-07 1999-04-15 Warner-Lambert Company Process for preparing a cyclic amino acid anticonvulsant compound
CU23048A3 (es) 1997-10-27 2005-06-24 Warner Lambert Co Aminoacidos ciclicos y derivados de los mismos, utiles como agentes farmaceuticos
EP1077691B1 (de) * 1998-05-15 2008-09-10 Warner-Lambert Company LLC Gamma-aminobuttersäurederivate enthaltende, feste arzneimittel und verfahren zu ihrer herstellung
DK1077692T3 (da) 1998-05-15 2004-12-06 Warner Lambert Co Aminosyrestabiliserede gabapentin- og pregabalinpræparater og fremgangsmåder til fremstilling deraf
WO1999061424A1 (en) 1998-05-26 1999-12-02 Warner-Lambert Company Conformationally constrained amino acid compounds having affinity for the alpha2delta subunit of a calcium channel
KR20010071778A (ko) * 1998-07-09 2001-07-31 로즈 암스트롱, 크리스틴 에이. 트러트웨인 불면증의 치료를 위한 ｇａｂａ 유사체의 용도
EP1121114B1 (de) * 1998-10-16 2007-01-10 Warner-Lambert Company Llc Verwendung von gaba analogen zur herstellung eines arzneimittels zur behandlung von manie und bipolaren erkrankungen
WO2000073300A1 (en) * 1999-06-02 2000-12-07 Warner-Lambert Company Amino heterocycles useful as pharmaceutical agents
AP2002002501A0 (en) * 1999-10-07 2002-06-30 Warner Lambert Co Synergistic combinations of an NK1 receptor antagonist and a gaba structural analog.
HUP0301919A3 (en) * 2000-06-16 2006-01-30 Teva Pharma Stable gabapentin having ph within a controlled range
SK17922002A3 (sk) * 2000-06-26 2003-11-04 Warner-Lambert Company Obdoby gabapentínu na liečenie porúch spánku
ITMI20012750A1 (it) 2001-12-21 2003-06-21 Procos Spa Processo per la produzione dell'acido 1-(amminometil)-cicloesil-acetico in forma pura
US20030119908A1 (en) * 2001-12-21 2003-06-26 Zambon Group S.P.A. Stable gabapentin compositions
CA2451267A1 (en) * 2002-12-13 2004-06-13 Warner-Lambert Company Llc Pharmaceutical uses for alpha2delta ligands
EP2575798B1 (de) 2010-06-01 2017-08-09 Rubicon Research Private Limited Gastroretentive dosierungszubereitung von gaba analoga
WO2015144825A1 (en) 2014-03-27 2015-10-01 Sanovel Ilac Sanayi Ve Ticaret A.S. Oral liquid pharmaceutical solution of gabapentin
US11670410B1 (en) * 2022-04-13 2023-06-06 Green Sky Creations LLC Systems and methods to automatically administer a psychoactive substance to an airway of a user based on a detected event or condition

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4087544A (en) * 1974-12-21 1978-05-02 Warner-Lambert Company Treatment of cranial dysfunctions using novel cyclic amino acids
DE2460891C2 (de) * 1974-12-21 1982-09-23 Gödecke AG, 1000 Berlin 1-Aminomethyl-1-cycloalkanessigsäuren und deren Ester, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel
US4355044A (en) * 1980-12-19 1982-10-19 Bernardo Heller D-Phenylalanine treatment
US5084479A (en) * 1990-01-02 1992-01-28 Warner-Lambert Company Novel methods for treating neurodegenerative diseases
US5086072A (en) * 1990-06-18 1992-02-04 The United States Of America As Represented By The Department Of Health And Human Services Treatment of mood disorders with functional antagonists of the glycine/nmda receptor complex
US5025035A (en) * 1990-10-12 1991-06-18 Warner-Lambert Company Method of treating depression

Also Published As

Publication number Publication date
EP0825857A1 (de) 1998-03-04
EP0825857B1 (de) 2002-06-12
ES2177783T3 (es) 2002-12-16
PT825857E (pt) 2002-11-29
NZ307366A (en) 1999-10-28
NO315967B1 (no) 2003-11-24
CZ355897A3 (cs) 1998-02-18
CA2215923A1 (en) 1996-11-21
ATE218857T1 (de) 2002-06-15
WO1996036328A1 (en) 1996-11-21
ZA963826B (en) 1996-11-21
DE69621799T2 (de) 2003-01-02
HUP9802087A2 (hu) 1998-12-28
SK152897A3 (en) 1999-05-07
EE9700302A (et) 1998-06-15
GEP20002014B (en) 2000-04-10
MX9707269A (es) 1997-11-29
DK0825857T3 (da) 2002-09-30
EE03420B1 (et) 2001-06-15
CZ288072B6 (cs) 2001-04-11
AU5668996A (en) 1996-11-29
CA2215923C (en) 2001-10-09
AU702435B2 (en) 1999-02-18
JPH11505244A (ja) 1999-05-18
NO975234D0 (no) 1997-11-14
NO975234L (no) 1997-11-14
SK281982B6 (sk) 2001-09-11
HUP9802087A3 (en) 1999-08-30
US5510381A (en) 1996-04-23

Similar Documents

Publication Publication Date Title
DE69621799D1 (de) Verwendung von gabapentin und seine derivate in der behandlung von manie und bipolare störungen
CY1106020T1 (el) Χρηση αναλογων caba για την βιομηχανικη κατασκευη ενος φαρμακου για την θepαπεια μανιας και διπολικων διαταραχων
ATE142877T1 (de) Melatoninderivate zur behandlung von schlafstörungen und zur pre-anästhesie
DE50015700D1 (de) Substituierte indole zur modulierung von nfkb-aktivität
ATE203019T1 (de) Neue (r)-5-carbamoyl-8-fluor-3-n,n- disubstituierte-amino-3,4-dihydro-2h-1- benzopyrane
DE69331605D1 (de) Verwendung von phenserin zur herstellung von medikamenten zur behandlung von kognitiven störungen
DE69631478D1 (de) Verwendung von vitamin d4-derivaten zur behandlung von hauterkrankungen
DE69626539D1 (de) topische Verwendung von Vitamin D zur Behandlung von Augenerkrankungen
ATE357438T1 (de) 1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
CY1106155T1 (el) Χρηση παραγωγων 3-βενζολοφαινυλοξικων οξεων για την αντιμετωπιση διαταραχων του αμφιβληστροειδους
DE69201660D1 (de) Verwendung von Acetyl L-Carnitin zur therapeutischen Behandlung von Coma.
TR200101149T2 (tr) Dış retina bozukluklarının tedavisi.
BR0014372A (pt) Derivados de 5-hidroxissapogenina com atividade antidemência
ATE235915T1 (de) Behandlung von hämorrhagischem virusfieber mit protein c
RU94040886A (ru) Применение производных мелатонина для лечения нарушений сна, фармацевтическая композиция
DE69309790D1 (de) Cyclopentanperhydrophenanthren-17-beta-(3-Furyl)-3-Derivate und pharmazeutische Präparate davon, zur Behandlung von Kardiovaskulär-Erkrankungen
DE69619051D1 (de) Behandlung von Füllstoffen mit Oxasilacycloalkanen
ATE261724T1 (de) Antikonvulsive derivate zur behandlung von posttraumatischen stresserkrankungen
DE59708511D1 (de) Verwendung von 7-(1-aminomethyl-2-oxa-7-aza-bicyclo 3.3.0]oct-7-yl)-chinoloncarbonsäure- und -naphthyridoncarbonsäure-derivaten zur therapie von helicobacter-pylori-infektionen und den damit assoziierten gastroduodenalen erkrankungen
DE59609977D1 (de) Trapidil zur verwendung in der therapie von immunmodulatorisch beeinflussbaren krankheitsbildern
DE69300037D1 (de) Verwendung von Bucillamin zur Herstellung eines Arzneimittels zur Behandlung von Cystinuria.
ES2144857T3 (es) Utilizacion de derivados benzonaftalenicos para la fabricacion de medicamentos destinados para el tratamiento de las enfermedades del sistema nervioso.
KR960003718A (ko) 말초신경병 및 중추신경변성병의 치료에 유용한 의약의 제조를 위한 이펜프로딜 및 그 부분입체이성질체의 이용
DE69807586D1 (de) Verwendung eines Alkylendioxybenzolderivats zur Behandlung von zirkadianen Schlafstörungen
DE68906028D1 (de) Verwendung von acetyl-d-carnitin zur therapeutischen behandlung von glaukom.

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8339 Ceased/non-payment of the annual fee